Navigation Links
Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
Date:7/24/2008

Pre-Clinical Data Shows Increased Muscle and Blood Vessel Formation in

Animals' Hearts

SUNRISE, Fla., July 24 /PRNewswire-FirstCall/ -- Results of a preclinical study involving the injection of myoblasts modified to express stromal derived factor-1(alpha) protein (SDF-1) into the scar tissue of the myocardium of rats, which suggest improved heart function, were recently presented at two scientific meetings -- the International Society for Magnetic Resonance in Medicine (ISMRM) in Toronto, and the American Society of Gene Therapy Meeting (ASGT) in Boston.

The data, presented by Bijoy Thattaliyath, MD, Post-doctoral Associate, Department of Pediatric Cardiology, University of Florida Health Science Center, showed a decrease of 0.02ml in end systolic volume (0.13ml to 0.11ml) and a 38 percent increase in stroke volume (0.31 ml to 0.43 ml) from three weeks post-myocardial infarction (MI, heart attack) to eight weeks post-cell transplantation, as presented in one of the SDF-1 modified myoblast (SDF-MB) transplanted animals. These results are indicative of 'positive remodeling', or return to normal heart function in the same period. Similar results were found in other study animals. Histopathology confirmed that myoblasts expressing SDF-1 resulted in increased muscle and blood vessel formation in the damaged areas of the hearts, which was not observed in the control.

Additionally, there was an 11.7 percent plus or minus 2.9 percent (p=0.02) absolute improvement in ejection fraction between three weeks post-MI and eight weeks post-cell transplantation in the SDF-MB treated animals. By comparison, and as anticipated, the control arm worsened in the same period. Ejection fraction is the percentage of blood pumped out of the heart's left ventricle with every heartbeat into the body's vasculature. A higher percent ejection fraction means more efficient heart function.

"The study data suggest that SDF-1 modified
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
4. GeoVax Reports Progress on Its AIDS Vaccine Technology
5. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
6. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
7. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
8. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
9. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
10. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:7/10/2014)... on aggression, who research issues ranging from child abuse ... Meeting of the International Society for Research on Aggression ... Georgia State University is hosting the prestigious world meeting, ... , "We are excited to be bringing together leading ... help produce fresh ideas about the causes, consequences and ...
(Date:7/10/2014)... The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. , ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization. ...
(Date:7/10/2014)... shown that more severe illness and even death are ... infection after developing influenza. Now, however, a team of ... if you reverse the order of infection, the bacteria ... protect against a bad case of the flu. ... which is described as a bacterial virulence factor, might ...
(Date:7/10/2014)... Biomedical Research Institute (IDIBELL) and the Catalan Institute of ... new therapeutic combination to combat resistant sarcomas. The clinical ... stabilize the growth of these tumors have been published ... ., Sarcomas , Sarcomas are a rare type ... It can affect from children to older ages. It ...
(Date:7/9/2014)... The World Health Organization recommends that youth participate in ... physical activity (MVPA) each day. Studies have shown ... hours. Therefore, it stands to reason that increasing ... In a new study scheduled for publication in The ... spent outdoors after school was positively associated with MVPA. ...
Breaking Medicine News(10 mins):Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2
... June 4 The Minneapolis-St. Paul office of Weber ... Program to head the organization,s largest annual awareness campaign. ... 8-22, will work to reach a diverse audience of ... thousands of people with leukemia and other life-threatening diseases, ...
... June 4 A cooking revolution is underway in the Kiboga district ... that the double Rocket Lorena stove is making it easier to cook ... money maker for youth in the community and are not as harmful ... out a local mixture of grass, water and mud. And for youth ...
... Mich. At the ends of chromosome are special pieces of ... caps off a shoelace. The telomeres send signals to the cells ... that should be repaired. Over time, as cells reproduce, the ... cells then have a higher risk of mutating into cancer. ...
... congestion is an important mediator in heart failure, reports ... Journal of Cardiac Failure ( http://www.onlinejcf.com/ ), published ... venous endothelium is a key regulator of central blood ... The present study demonstrates that in venous endothelium, ...
... ... Approval , ... June 4, 2009-- A new wrinkle-smoother will be arriving in doctors, offices in July: ... Union, Brazil, Argentina and more than 26 countries worldwide is a form of botulinum ...
... Nutrition Program from Fitness Expert Monique Hollowell , ... their bodies will never be the same following pregnancy ... pregnancy, less painful birth and quick recovery back to ... trainer, Monique Hollowell has created a fitness and nutrition ...
Cached Medicine News:Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 2Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 3Health News:Youth-made Stoves Provide Income, Protect the Environment 2Health News:Study gives clues to how adrenal cancer forms 2Health News:New Option for Erasing Wrinkles 2Health News:New Option for Erasing Wrinkles 3Health News:New Option for Erasing Wrinkles 4Health News:Keys to a Fit Pregnancy and Losing the Baby Weight 2Health News:Keys to a Fit Pregnancy and Losing the Baby Weight 3
Fluar objectives have been designed especially for qualitative and quantitative analyses of ion movements and for particularly critical fluorescence methods (e.g. chromosome studies in human and cyto...
... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...
... transmission rate in the ultraviolet down to ... fluor-3; these objectives have,improved signal to noise ... Numerical Apertures for significantly sharper and brighter ... and a 2mm working distance to allow ...
... distances with high Numerical Apertures, these objectives ... aberrations throughout the visible spectrum from violet ... the entire 25mm field of view. They ... reproduction, plus resolving power at the theoretical ...
Medicine Products: